AUA SIU Symposium Therapeutic Advances In Immuno - Oncology
The American Urological Association (AUA) and Società Italiana di Urologia (SIU) have collaborated to develop an independent educational activity to review the latest updates in immuno-oncology. This...
5 Marras 201950min
Immune Checkpoint Inhibitors In Renal Cell Carcinoma
Co-Host: William Huang, MD At the conclusion of these activities, participants will be able to: 1. Discuss the current immunotherapy options available for the treatment of RCC. 2. Describe both compl...
31 Loka 201935min
AUA2019 Take Home Messages - Female Urology And Incontinence - Reconstruction
Take Home Messages: Female Urology/Incontinence Ariana Smith, MD University of Pennsylvania Take Home Messages: Reconstruction Giulia Lane, MD Urology Fellow, FPMRS University of Michigan
25 Loka 201916min
Sequencing Of Agents And Combination Therapy In Castrate Resistant Prostate Cancer
Co-Host: Maxwell Meng, MD At the conclusion of these activities, participants will be able to: 1. Identify treatments for non-metastatic and metastatic CRPC and describe the proper order for their ad...
17 Loka 201938min
The Role of Immune Checkpoint Inhibitors in Bladder Cancer
Co-Host: Robert Svatek, MD At the conclusion of these activities, participants will be able to: 1. Recognize both historic and newer immunotherapy options in the treatment of bladder cancer. 2. Descr...
10 Loka 201931min
Treatment For Metastatic Hormone Sensitive Prostate Cancer (M - HSPC)
Co-Host: Kelvin Moses, MD At the conclusion of these activities, participants will be able to: 1. Identify the active agents and their mechanism of action in the management of metastatic HSPC. 2. Des...
3 Loka 201923min
Update Series v38l1 Diagnosis And Management Of Pheochromocytoma
Please enjoy this free lesson of the AUA Update Series Volume 38 Lesson 1: Diagnosis and Management of Pheochromocytoma Please send any comments to education@auanet.org
30 Syys 201924min
Clinical Investigations in the Treatment of Urothelial Carcinoma
Co-Host: Yair Lotan, MD At the conclusion of these activities, participants will be able to: 1. Explain the scientific rationale for investigating immune oncology agents for BCG unresponsive disease...
25 Syys 201925min
